Relative to pharmaceutical access, costs and transparency. A pharmaceutical manufacturing company shall provide early notice to the commission if it plans to increase the wholesale acquisition cost of a: (i) brand-name drug by more than 20 per cent per wholesale acquisition cost unit during any 12-month period; or (ii) generic drug priced at $100 or more per wholesale acquisition cost unit by 200 per cent or more during any 12-month period.